The RADICAL PC Project - Jehonathan Pinthus
Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one year of their first diagnosis of prostate cancer, or who are within one month of commencing ADT for the first time. The study's goal is to identify factors associated with the development of CVD among men with prostate cancer, with a particular focus on ADT. The Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2) is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a systematic approach to modifying CV and lifestyle risk factors.
Clinical Trial Information on RADICAL PC
Jehonathan H. Pinthus, MD, PhD, FRCSC is a surgical oncologist-urologist and associate Professor in the Department of Surgery Division of Urology McMaster University. Dr. Pinthus is the principle investigator on many research grants the most recent one being the Movember-Prostate Cancer Canada grant titled "Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC)" to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease.
Thomas E. Keane
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: A meta-analysis of population-based observational studies
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials